hexamethonium has been researched along with Anorexia in 1 studies
Hexamethonium: A nicotinic cholinergic antagonist often referred to as the prototypical ganglionic blocker. It is poorly absorbed from the gastrointestinal tract and does not cross the blood-brain barrier. It has been used for a variety of therapeutic purposes including hypertension but, like the other ganglionic blockers, it has been replaced by more specific drugs for most purposes, although it is widely used a research tool.
Anorexia: The lack or loss of APPETITE accompanied by an aversion to food and the inability to eat. It is the defining characteristic of the disorder ANOREXIA NERVOSA.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zarrindast, MR | 1 |
| Oveisi, MR | 1 |
1 other study available for hexamethonium and Anorexia
| Article | Year |
|---|---|
Effects of monoamine receptor antagonists on nicotine-induced hypophagia in the rat.
Topics: Adrenergic Antagonists; Animals; Anorexia; Atropine; Cholinergic Agents; Cholinergic Antagonists; Do | 1997 |